Unitaid Calls For Proposals To Develop Technologies To Treat Malaria, HIV, TB 13/02/2019 by David Branigan Unitaid has launched two separate calls for proposals for the development of improved technologies to better diagnose and treat Plasmodium vivax malaria, and to more effectively treat HIV and its coinfections, including tuberculosis and malaria, in low and middle-income countries. Continue reading -> WHO Governance Questioned As It Adds World Health Assembly Agenda Item On Biodiversity 01/02/2019 by Catherine Saez The World Health Organization today admitted to an unusual procedure to set up a debate on the health implications of a UN treaty on sharing of benefits from genetic resources. The new agenda item proposed by the WHO director general was accepted by the WHO Board today, but with member states questioning the governance of the move. Continue reading -> Board Debates WHO Plans For Efficiencies At Headquarters & Funding Shifts To Countries 25/01/2019 by Elaine Ruth Fletcher A massive restructuring of WHO’s 2020-2021 budget should see a shift away from siloed disease control programmes to a more integrated approach, focused on building health systems and strengthening country operations. These were the key strategic features of the proposed budget of US$ 4.785 billion, reviewed by WHO’s Executive Board in a lengthy session today. Continue reading -> Top Global Health Policy Issues – What To Watch In 2019 23/01/2019 by David Branigan When historians look back, will this year mark a turning point in global health? Certainly some of the big issues on the agenda in 2019 might suggest that we are at a crossroads. We can expect to see an intensification of the push for universal health coverage (UHC), culminating with a first-ever high-level United Nations meeting, and a shift away from disease-specific interventions towards more integrated approaches. Health Policy Watch spoke with a range of leading global health policy experts from the World Health Organization (WHO), NGOs, industry and foundations to get their take on the top issues, and here is what they said to watch for in 2019 in five priority areas. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 by Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Tanzania’s New Health Policy To Recognise Neglected Tropical Diseases 11/12/2018 by Kizito Makoye TABORA, Tanzania -- At first glance, the village looks quiet and beautiful. Unfortunately, life has not been affirming for dozens of its inhabitants. They have leprosy—a least contagious and curable disease, except for its two worst characteristics — poverty and neglect. Continue reading -> First WHO Global Coordination Meeting On NCDs Sets Actions For Future 07/11/2018 by Catherine Saez According to the World Health Organization, noncommunicable diseases (NCDs) - or chronic diseases - including cancer, cardiovascular diseases, and diabetes, kill 41 million people each year and are on the rise in developing countries. This week, the WHO held the first general meeting of its mechanism aiming at facilitating prevention and control of NCD diseases. The numerous speakers shared local, regional, and international experiences in implementing measures. Separately, WHO announced the launch of a new collaborative platform for NCDs. Continue reading -> Tobacco Convention Chief Hails Advances But Offers Warnings And Flags Concerns Tobacco Industry Continues “Furious Efforts” To Undermine Treaty 02/10/2018 by John Zarocostas The chief of the Framework Convention on Tobacco Control Secretariat, Vera Luiza da Costa e Silva, told delegates from its 181 member states attending a Conference of the Parties meeting in Geneva (1-6 October) many governments have advanced tobacco control actions, but also noted some are lagging behind and warned that with astronomical budgets, the tobacco industry "continues their furious efforts" to undermine the implementation of the treaty. Continue reading -> Patent Backlogs Fuel Efforts To Extend Pharma Patent Terms In Thailand And Brazil, AIDS Activists Say 18/05/2018 by Dugie Standeford For a variety of reasons, Thailand and Brazil have huge backlogs of pharmaceutical patent applications. The delay in patent examinations is creating pressure on the countries to extend patent protection terms to the detriment of access to affordable medicines, AIDS organisations say. Continue reading -> The Patent Paradox In Brazil And Its Implications For Access To Medicines 18/05/2018 by Guest contributor Brazil is frequently pointed to as one of the countries in which fewer pharmaceutical patents are granted. The fact that there is a low number of patents granted could lead to the conclusion that medicines can be bought under competition and that the prices would be low. However, many medicines in Brazil are bought exclusively from one producer and usually at high prices. The situation of few granted patents, but many purchases under exclusivity due to absence of competition (which can lead to higher prices), is what we are calling the ‘patent paradox in Brazil’. In the absence of granted patents, what are the factors that lead to the situation of no competition and high prices in Brazil? This is the question that we, at the accessibsa: Innovation & Access to Medicines in India, Brazil & South Africa, aim to answer with a study currently being conducted at the Department of Medicines Policy and Pharmaceutical Services (NAF) of the Sergio Arouca National School of Public Health – ENSP/Fiocruz. Continue reading -> Posts navigation Older posts
WHO Governance Questioned As It Adds World Health Assembly Agenda Item On Biodiversity 01/02/2019 by Catherine Saez The World Health Organization today admitted to an unusual procedure to set up a debate on the health implications of a UN treaty on sharing of benefits from genetic resources. The new agenda item proposed by the WHO director general was accepted by the WHO Board today, but with member states questioning the governance of the move. Continue reading -> Board Debates WHO Plans For Efficiencies At Headquarters & Funding Shifts To Countries 25/01/2019 by Elaine Ruth Fletcher A massive restructuring of WHO’s 2020-2021 budget should see a shift away from siloed disease control programmes to a more integrated approach, focused on building health systems and strengthening country operations. These were the key strategic features of the proposed budget of US$ 4.785 billion, reviewed by WHO’s Executive Board in a lengthy session today. Continue reading -> Top Global Health Policy Issues – What To Watch In 2019 23/01/2019 by David Branigan When historians look back, will this year mark a turning point in global health? Certainly some of the big issues on the agenda in 2019 might suggest that we are at a crossroads. We can expect to see an intensification of the push for universal health coverage (UHC), culminating with a first-ever high-level United Nations meeting, and a shift away from disease-specific interventions towards more integrated approaches. Health Policy Watch spoke with a range of leading global health policy experts from the World Health Organization (WHO), NGOs, industry and foundations to get their take on the top issues, and here is what they said to watch for in 2019 in five priority areas. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 by Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Tanzania’s New Health Policy To Recognise Neglected Tropical Diseases 11/12/2018 by Kizito Makoye TABORA, Tanzania -- At first glance, the village looks quiet and beautiful. Unfortunately, life has not been affirming for dozens of its inhabitants. They have leprosy—a least contagious and curable disease, except for its two worst characteristics — poverty and neglect. Continue reading -> First WHO Global Coordination Meeting On NCDs Sets Actions For Future 07/11/2018 by Catherine Saez According to the World Health Organization, noncommunicable diseases (NCDs) - or chronic diseases - including cancer, cardiovascular diseases, and diabetes, kill 41 million people each year and are on the rise in developing countries. This week, the WHO held the first general meeting of its mechanism aiming at facilitating prevention and control of NCD diseases. The numerous speakers shared local, regional, and international experiences in implementing measures. Separately, WHO announced the launch of a new collaborative platform for NCDs. Continue reading -> Tobacco Convention Chief Hails Advances But Offers Warnings And Flags Concerns Tobacco Industry Continues “Furious Efforts” To Undermine Treaty 02/10/2018 by John Zarocostas The chief of the Framework Convention on Tobacco Control Secretariat, Vera Luiza da Costa e Silva, told delegates from its 181 member states attending a Conference of the Parties meeting in Geneva (1-6 October) many governments have advanced tobacco control actions, but also noted some are lagging behind and warned that with astronomical budgets, the tobacco industry "continues their furious efforts" to undermine the implementation of the treaty. Continue reading -> Patent Backlogs Fuel Efforts To Extend Pharma Patent Terms In Thailand And Brazil, AIDS Activists Say 18/05/2018 by Dugie Standeford For a variety of reasons, Thailand and Brazil have huge backlogs of pharmaceutical patent applications. The delay in patent examinations is creating pressure on the countries to extend patent protection terms to the detriment of access to affordable medicines, AIDS organisations say. Continue reading -> The Patent Paradox In Brazil And Its Implications For Access To Medicines 18/05/2018 by Guest contributor Brazil is frequently pointed to as one of the countries in which fewer pharmaceutical patents are granted. The fact that there is a low number of patents granted could lead to the conclusion that medicines can be bought under competition and that the prices would be low. However, many medicines in Brazil are bought exclusively from one producer and usually at high prices. The situation of few granted patents, but many purchases under exclusivity due to absence of competition (which can lead to higher prices), is what we are calling the ‘patent paradox in Brazil’. In the absence of granted patents, what are the factors that lead to the situation of no competition and high prices in Brazil? This is the question that we, at the accessibsa: Innovation & Access to Medicines in India, Brazil & South Africa, aim to answer with a study currently being conducted at the Department of Medicines Policy and Pharmaceutical Services (NAF) of the Sergio Arouca National School of Public Health – ENSP/Fiocruz. Continue reading -> Posts navigation Older posts
Board Debates WHO Plans For Efficiencies At Headquarters & Funding Shifts To Countries 25/01/2019 by Elaine Ruth Fletcher A massive restructuring of WHO’s 2020-2021 budget should see a shift away from siloed disease control programmes to a more integrated approach, focused on building health systems and strengthening country operations. These were the key strategic features of the proposed budget of US$ 4.785 billion, reviewed by WHO’s Executive Board in a lengthy session today. Continue reading -> Top Global Health Policy Issues – What To Watch In 2019 23/01/2019 by David Branigan When historians look back, will this year mark a turning point in global health? Certainly some of the big issues on the agenda in 2019 might suggest that we are at a crossroads. We can expect to see an intensification of the push for universal health coverage (UHC), culminating with a first-ever high-level United Nations meeting, and a shift away from disease-specific interventions towards more integrated approaches. Health Policy Watch spoke with a range of leading global health policy experts from the World Health Organization (WHO), NGOs, industry and foundations to get their take on the top issues, and here is what they said to watch for in 2019 in five priority areas. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 by Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Tanzania’s New Health Policy To Recognise Neglected Tropical Diseases 11/12/2018 by Kizito Makoye TABORA, Tanzania -- At first glance, the village looks quiet and beautiful. Unfortunately, life has not been affirming for dozens of its inhabitants. They have leprosy—a least contagious and curable disease, except for its two worst characteristics — poverty and neglect. Continue reading -> First WHO Global Coordination Meeting On NCDs Sets Actions For Future 07/11/2018 by Catherine Saez According to the World Health Organization, noncommunicable diseases (NCDs) - or chronic diseases - including cancer, cardiovascular diseases, and diabetes, kill 41 million people each year and are on the rise in developing countries. This week, the WHO held the first general meeting of its mechanism aiming at facilitating prevention and control of NCD diseases. The numerous speakers shared local, regional, and international experiences in implementing measures. Separately, WHO announced the launch of a new collaborative platform for NCDs. Continue reading -> Tobacco Convention Chief Hails Advances But Offers Warnings And Flags Concerns Tobacco Industry Continues “Furious Efforts” To Undermine Treaty 02/10/2018 by John Zarocostas The chief of the Framework Convention on Tobacco Control Secretariat, Vera Luiza da Costa e Silva, told delegates from its 181 member states attending a Conference of the Parties meeting in Geneva (1-6 October) many governments have advanced tobacco control actions, but also noted some are lagging behind and warned that with astronomical budgets, the tobacco industry "continues their furious efforts" to undermine the implementation of the treaty. Continue reading -> Patent Backlogs Fuel Efforts To Extend Pharma Patent Terms In Thailand And Brazil, AIDS Activists Say 18/05/2018 by Dugie Standeford For a variety of reasons, Thailand and Brazil have huge backlogs of pharmaceutical patent applications. The delay in patent examinations is creating pressure on the countries to extend patent protection terms to the detriment of access to affordable medicines, AIDS organisations say. Continue reading -> The Patent Paradox In Brazil And Its Implications For Access To Medicines 18/05/2018 by Guest contributor Brazil is frequently pointed to as one of the countries in which fewer pharmaceutical patents are granted. The fact that there is a low number of patents granted could lead to the conclusion that medicines can be bought under competition and that the prices would be low. However, many medicines in Brazil are bought exclusively from one producer and usually at high prices. The situation of few granted patents, but many purchases under exclusivity due to absence of competition (which can lead to higher prices), is what we are calling the ‘patent paradox in Brazil’. In the absence of granted patents, what are the factors that lead to the situation of no competition and high prices in Brazil? This is the question that we, at the accessibsa: Innovation & Access to Medicines in India, Brazil & South Africa, aim to answer with a study currently being conducted at the Department of Medicines Policy and Pharmaceutical Services (NAF) of the Sergio Arouca National School of Public Health – ENSP/Fiocruz. Continue reading -> Posts navigation Older posts
Top Global Health Policy Issues – What To Watch In 2019 23/01/2019 by David Branigan When historians look back, will this year mark a turning point in global health? Certainly some of the big issues on the agenda in 2019 might suggest that we are at a crossroads. We can expect to see an intensification of the push for universal health coverage (UHC), culminating with a first-ever high-level United Nations meeting, and a shift away from disease-specific interventions towards more integrated approaches. Health Policy Watch spoke with a range of leading global health policy experts from the World Health Organization (WHO), NGOs, industry and foundations to get their take on the top issues, and here is what they said to watch for in 2019 in five priority areas. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 by Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Tanzania’s New Health Policy To Recognise Neglected Tropical Diseases 11/12/2018 by Kizito Makoye TABORA, Tanzania -- At first glance, the village looks quiet and beautiful. Unfortunately, life has not been affirming for dozens of its inhabitants. They have leprosy—a least contagious and curable disease, except for its two worst characteristics — poverty and neglect. Continue reading -> First WHO Global Coordination Meeting On NCDs Sets Actions For Future 07/11/2018 by Catherine Saez According to the World Health Organization, noncommunicable diseases (NCDs) - or chronic diseases - including cancer, cardiovascular diseases, and diabetes, kill 41 million people each year and are on the rise in developing countries. This week, the WHO held the first general meeting of its mechanism aiming at facilitating prevention and control of NCD diseases. The numerous speakers shared local, regional, and international experiences in implementing measures. Separately, WHO announced the launch of a new collaborative platform for NCDs. Continue reading -> Tobacco Convention Chief Hails Advances But Offers Warnings And Flags Concerns Tobacco Industry Continues “Furious Efforts” To Undermine Treaty 02/10/2018 by John Zarocostas The chief of the Framework Convention on Tobacco Control Secretariat, Vera Luiza da Costa e Silva, told delegates from its 181 member states attending a Conference of the Parties meeting in Geneva (1-6 October) many governments have advanced tobacco control actions, but also noted some are lagging behind and warned that with astronomical budgets, the tobacco industry "continues their furious efforts" to undermine the implementation of the treaty. Continue reading -> Patent Backlogs Fuel Efforts To Extend Pharma Patent Terms In Thailand And Brazil, AIDS Activists Say 18/05/2018 by Dugie Standeford For a variety of reasons, Thailand and Brazil have huge backlogs of pharmaceutical patent applications. The delay in patent examinations is creating pressure on the countries to extend patent protection terms to the detriment of access to affordable medicines, AIDS organisations say. Continue reading -> The Patent Paradox In Brazil And Its Implications For Access To Medicines 18/05/2018 by Guest contributor Brazil is frequently pointed to as one of the countries in which fewer pharmaceutical patents are granted. The fact that there is a low number of patents granted could lead to the conclusion that medicines can be bought under competition and that the prices would be low. However, many medicines in Brazil are bought exclusively from one producer and usually at high prices. The situation of few granted patents, but many purchases under exclusivity due to absence of competition (which can lead to higher prices), is what we are calling the ‘patent paradox in Brazil’. In the absence of granted patents, what are the factors that lead to the situation of no competition and high prices in Brazil? This is the question that we, at the accessibsa: Innovation & Access to Medicines in India, Brazil & South Africa, aim to answer with a study currently being conducted at the Department of Medicines Policy and Pharmaceutical Services (NAF) of the Sergio Arouca National School of Public Health – ENSP/Fiocruz. Continue reading -> Posts navigation Older posts
Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 by Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Tanzania’s New Health Policy To Recognise Neglected Tropical Diseases 11/12/2018 by Kizito Makoye TABORA, Tanzania -- At first glance, the village looks quiet and beautiful. Unfortunately, life has not been affirming for dozens of its inhabitants. They have leprosy—a least contagious and curable disease, except for its two worst characteristics — poverty and neglect. Continue reading -> First WHO Global Coordination Meeting On NCDs Sets Actions For Future 07/11/2018 by Catherine Saez According to the World Health Organization, noncommunicable diseases (NCDs) - or chronic diseases - including cancer, cardiovascular diseases, and diabetes, kill 41 million people each year and are on the rise in developing countries. This week, the WHO held the first general meeting of its mechanism aiming at facilitating prevention and control of NCD diseases. The numerous speakers shared local, regional, and international experiences in implementing measures. Separately, WHO announced the launch of a new collaborative platform for NCDs. Continue reading -> Tobacco Convention Chief Hails Advances But Offers Warnings And Flags Concerns Tobacco Industry Continues “Furious Efforts” To Undermine Treaty 02/10/2018 by John Zarocostas The chief of the Framework Convention on Tobacco Control Secretariat, Vera Luiza da Costa e Silva, told delegates from its 181 member states attending a Conference of the Parties meeting in Geneva (1-6 October) many governments have advanced tobacco control actions, but also noted some are lagging behind and warned that with astronomical budgets, the tobacco industry "continues their furious efforts" to undermine the implementation of the treaty. Continue reading -> Patent Backlogs Fuel Efforts To Extend Pharma Patent Terms In Thailand And Brazil, AIDS Activists Say 18/05/2018 by Dugie Standeford For a variety of reasons, Thailand and Brazil have huge backlogs of pharmaceutical patent applications. The delay in patent examinations is creating pressure on the countries to extend patent protection terms to the detriment of access to affordable medicines, AIDS organisations say. Continue reading -> The Patent Paradox In Brazil And Its Implications For Access To Medicines 18/05/2018 by Guest contributor Brazil is frequently pointed to as one of the countries in which fewer pharmaceutical patents are granted. The fact that there is a low number of patents granted could lead to the conclusion that medicines can be bought under competition and that the prices would be low. However, many medicines in Brazil are bought exclusively from one producer and usually at high prices. The situation of few granted patents, but many purchases under exclusivity due to absence of competition (which can lead to higher prices), is what we are calling the ‘patent paradox in Brazil’. In the absence of granted patents, what are the factors that lead to the situation of no competition and high prices in Brazil? This is the question that we, at the accessibsa: Innovation & Access to Medicines in India, Brazil & South Africa, aim to answer with a study currently being conducted at the Department of Medicines Policy and Pharmaceutical Services (NAF) of the Sergio Arouca National School of Public Health – ENSP/Fiocruz. Continue reading -> Posts navigation Older posts
Tanzania’s New Health Policy To Recognise Neglected Tropical Diseases 11/12/2018 by Kizito Makoye TABORA, Tanzania -- At first glance, the village looks quiet and beautiful. Unfortunately, life has not been affirming for dozens of its inhabitants. They have leprosy—a least contagious and curable disease, except for its two worst characteristics — poverty and neglect. Continue reading -> First WHO Global Coordination Meeting On NCDs Sets Actions For Future 07/11/2018 by Catherine Saez According to the World Health Organization, noncommunicable diseases (NCDs) - or chronic diseases - including cancer, cardiovascular diseases, and diabetes, kill 41 million people each year and are on the rise in developing countries. This week, the WHO held the first general meeting of its mechanism aiming at facilitating prevention and control of NCD diseases. The numerous speakers shared local, regional, and international experiences in implementing measures. Separately, WHO announced the launch of a new collaborative platform for NCDs. Continue reading -> Tobacco Convention Chief Hails Advances But Offers Warnings And Flags Concerns Tobacco Industry Continues “Furious Efforts” To Undermine Treaty 02/10/2018 by John Zarocostas The chief of the Framework Convention on Tobacco Control Secretariat, Vera Luiza da Costa e Silva, told delegates from its 181 member states attending a Conference of the Parties meeting in Geneva (1-6 October) many governments have advanced tobacco control actions, but also noted some are lagging behind and warned that with astronomical budgets, the tobacco industry "continues their furious efforts" to undermine the implementation of the treaty. Continue reading -> Patent Backlogs Fuel Efforts To Extend Pharma Patent Terms In Thailand And Brazil, AIDS Activists Say 18/05/2018 by Dugie Standeford For a variety of reasons, Thailand and Brazil have huge backlogs of pharmaceutical patent applications. The delay in patent examinations is creating pressure on the countries to extend patent protection terms to the detriment of access to affordable medicines, AIDS organisations say. Continue reading -> The Patent Paradox In Brazil And Its Implications For Access To Medicines 18/05/2018 by Guest contributor Brazil is frequently pointed to as one of the countries in which fewer pharmaceutical patents are granted. The fact that there is a low number of patents granted could lead to the conclusion that medicines can be bought under competition and that the prices would be low. However, many medicines in Brazil are bought exclusively from one producer and usually at high prices. The situation of few granted patents, but many purchases under exclusivity due to absence of competition (which can lead to higher prices), is what we are calling the ‘patent paradox in Brazil’. In the absence of granted patents, what are the factors that lead to the situation of no competition and high prices in Brazil? This is the question that we, at the accessibsa: Innovation & Access to Medicines in India, Brazil & South Africa, aim to answer with a study currently being conducted at the Department of Medicines Policy and Pharmaceutical Services (NAF) of the Sergio Arouca National School of Public Health – ENSP/Fiocruz. Continue reading -> Posts navigation Older posts
First WHO Global Coordination Meeting On NCDs Sets Actions For Future 07/11/2018 by Catherine Saez According to the World Health Organization, noncommunicable diseases (NCDs) - or chronic diseases - including cancer, cardiovascular diseases, and diabetes, kill 41 million people each year and are on the rise in developing countries. This week, the WHO held the first general meeting of its mechanism aiming at facilitating prevention and control of NCD diseases. The numerous speakers shared local, regional, and international experiences in implementing measures. Separately, WHO announced the launch of a new collaborative platform for NCDs. Continue reading -> Tobacco Convention Chief Hails Advances But Offers Warnings And Flags Concerns Tobacco Industry Continues “Furious Efforts” To Undermine Treaty 02/10/2018 by John Zarocostas The chief of the Framework Convention on Tobacco Control Secretariat, Vera Luiza da Costa e Silva, told delegates from its 181 member states attending a Conference of the Parties meeting in Geneva (1-6 October) many governments have advanced tobacco control actions, but also noted some are lagging behind and warned that with astronomical budgets, the tobacco industry "continues their furious efforts" to undermine the implementation of the treaty. Continue reading -> Patent Backlogs Fuel Efforts To Extend Pharma Patent Terms In Thailand And Brazil, AIDS Activists Say 18/05/2018 by Dugie Standeford For a variety of reasons, Thailand and Brazil have huge backlogs of pharmaceutical patent applications. The delay in patent examinations is creating pressure on the countries to extend patent protection terms to the detriment of access to affordable medicines, AIDS organisations say. Continue reading -> The Patent Paradox In Brazil And Its Implications For Access To Medicines 18/05/2018 by Guest contributor Brazil is frequently pointed to as one of the countries in which fewer pharmaceutical patents are granted. The fact that there is a low number of patents granted could lead to the conclusion that medicines can be bought under competition and that the prices would be low. However, many medicines in Brazil are bought exclusively from one producer and usually at high prices. The situation of few granted patents, but many purchases under exclusivity due to absence of competition (which can lead to higher prices), is what we are calling the ‘patent paradox in Brazil’. In the absence of granted patents, what are the factors that lead to the situation of no competition and high prices in Brazil? This is the question that we, at the accessibsa: Innovation & Access to Medicines in India, Brazil & South Africa, aim to answer with a study currently being conducted at the Department of Medicines Policy and Pharmaceutical Services (NAF) of the Sergio Arouca National School of Public Health – ENSP/Fiocruz. Continue reading -> Posts navigation Older posts
Tobacco Convention Chief Hails Advances But Offers Warnings And Flags Concerns Tobacco Industry Continues “Furious Efforts” To Undermine Treaty 02/10/2018 by John Zarocostas The chief of the Framework Convention on Tobacco Control Secretariat, Vera Luiza da Costa e Silva, told delegates from its 181 member states attending a Conference of the Parties meeting in Geneva (1-6 October) many governments have advanced tobacco control actions, but also noted some are lagging behind and warned that with astronomical budgets, the tobacco industry "continues their furious efforts" to undermine the implementation of the treaty. Continue reading -> Patent Backlogs Fuel Efforts To Extend Pharma Patent Terms In Thailand And Brazil, AIDS Activists Say 18/05/2018 by Dugie Standeford For a variety of reasons, Thailand and Brazil have huge backlogs of pharmaceutical patent applications. The delay in patent examinations is creating pressure on the countries to extend patent protection terms to the detriment of access to affordable medicines, AIDS organisations say. Continue reading -> The Patent Paradox In Brazil And Its Implications For Access To Medicines 18/05/2018 by Guest contributor Brazil is frequently pointed to as one of the countries in which fewer pharmaceutical patents are granted. The fact that there is a low number of patents granted could lead to the conclusion that medicines can be bought under competition and that the prices would be low. However, many medicines in Brazil are bought exclusively from one producer and usually at high prices. The situation of few granted patents, but many purchases under exclusivity due to absence of competition (which can lead to higher prices), is what we are calling the ‘patent paradox in Brazil’. In the absence of granted patents, what are the factors that lead to the situation of no competition and high prices in Brazil? This is the question that we, at the accessibsa: Innovation & Access to Medicines in India, Brazil & South Africa, aim to answer with a study currently being conducted at the Department of Medicines Policy and Pharmaceutical Services (NAF) of the Sergio Arouca National School of Public Health – ENSP/Fiocruz. Continue reading -> Posts navigation Older posts
Patent Backlogs Fuel Efforts To Extend Pharma Patent Terms In Thailand And Brazil, AIDS Activists Say 18/05/2018 by Dugie Standeford For a variety of reasons, Thailand and Brazil have huge backlogs of pharmaceutical patent applications. The delay in patent examinations is creating pressure on the countries to extend patent protection terms to the detriment of access to affordable medicines, AIDS organisations say. Continue reading -> The Patent Paradox In Brazil And Its Implications For Access To Medicines 18/05/2018 by Guest contributor Brazil is frequently pointed to as one of the countries in which fewer pharmaceutical patents are granted. The fact that there is a low number of patents granted could lead to the conclusion that medicines can be bought under competition and that the prices would be low. However, many medicines in Brazil are bought exclusively from one producer and usually at high prices. The situation of few granted patents, but many purchases under exclusivity due to absence of competition (which can lead to higher prices), is what we are calling the ‘patent paradox in Brazil’. In the absence of granted patents, what are the factors that lead to the situation of no competition and high prices in Brazil? This is the question that we, at the accessibsa: Innovation & Access to Medicines in India, Brazil & South Africa, aim to answer with a study currently being conducted at the Department of Medicines Policy and Pharmaceutical Services (NAF) of the Sergio Arouca National School of Public Health – ENSP/Fiocruz. Continue reading -> Posts navigation Older posts
The Patent Paradox In Brazil And Its Implications For Access To Medicines 18/05/2018 by Guest contributor Brazil is frequently pointed to as one of the countries in which fewer pharmaceutical patents are granted. The fact that there is a low number of patents granted could lead to the conclusion that medicines can be bought under competition and that the prices would be low. However, many medicines in Brazil are bought exclusively from one producer and usually at high prices. The situation of few granted patents, but many purchases under exclusivity due to absence of competition (which can lead to higher prices), is what we are calling the ‘patent paradox in Brazil’. In the absence of granted patents, what are the factors that lead to the situation of no competition and high prices in Brazil? This is the question that we, at the accessibsa: Innovation & Access to Medicines in India, Brazil & South Africa, aim to answer with a study currently being conducted at the Department of Medicines Policy and Pharmaceutical Services (NAF) of the Sergio Arouca National School of Public Health – ENSP/Fiocruz. Continue reading -> Posts navigation Older posts